This narrative review looks at PROTACs, a type of drug, for treating conditions like cancer, immune modulation issues, and neurodegenerative diseases. The authors did not report a specific study size or patient population because this is a review of existing information rather than a new clinical trial.
The text highlights several challenges that currently limit the use of these drugs. These issues include suboptimal pharmacokinetic profiles and a stoichiometric hook effect. Additionally, there is a disproportionate reliance on a limited pool of E3 ligases, specifically cereblon and von Hippel-Lindau.
Because this is a narrative review and not a practice-changing study, readers should be cautious about how much they can take from it. No safety concerns or adverse events were reported in this specific document. The main reason to be careful is that the evidence is limited and does not yet support widespread clinical use.
